Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal

被引:5
作者
Toumi, Mondher [1 ,10 ]
Dabbous, Omar [2 ]
Aballea, Samuel [3 ]
Drummond, Michael F. [4 ]
von der Schulenburg, Johann-Matthias Graf [5 ]
Malone, Daniel C. [6 ]
Neumann, Peter J. [7 ]
Sullivan, Sean D. [8 ]
Tunis, Sean [9 ]
机构
[1] Aix Marseille Univ, Publ Hlth Dept, Lab Sante Publ, Marseille, France
[2] Novartis Gene Therapies Inc, Global Genecon & Outcomes Res, Bannockburn, IL USA
[3] Creativ Ceut, Paris, France
[4] Univ York, Ctr Hlth Econ, York, England
[5] Leibniz Univ Hannover, Inst Risk & Insurance, Hannover, Germany
[6] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA
[7] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[8] Univ Washington, CHOICE Inst, Seattle, WA USA
[9] Rubix Hlth, Baltimore, MD USA
[10] Aix Marseille Univ, Publ Hlth Dept, Lab Sante Publ, 27 Blvd Jean Moulin, F-13385 Marseille, France
关键词
Cost-effectiveness analysis; economic evaluation; gene therapy; health technology assessments; health-related quality of life; onasemnogene abeparvovec; spinal muscular atrophy; systematic literature review; COST-EFFECTIVENESS ANALYSIS; HEALTH TECHNOLOGY-ASSESSMENT; REGENERATIVE MEDICINES; VORETIGENE NEPARVOVEC; ADULT PATIENTS; CHALLENGES; TISAGENLECLEUCEL; LYMPHOMA; PRODUCTS;
D O I
10.1080/14737167.2023.2197214
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations for the economic evaluation of gene therapies and assess whether these recommendations have been applied in published evaluations.Methods: This study was conducted in three stages: a systematic literature review of methodologic recommendations for economic evaluation of gene therapies; an assessment of the appropriateness of recommendations; and a review to assess the degree to which the recommendations were applied in published evaluations.Results: A total of 2,888 references were screened, 83 articles were reviewed to assess eligibility, and 20 papers were included. Fifty recommendations were identified, and 21 reached consensus thresholds. Most evaluations were based on naive treatment comparisons and did not apply consensus recommendations. Innovative payment mechanisms for gene therapies were rarely considered. The only widely applied recommendations related to modeling choices and methods.Conclusions: Methodological recommendations for economic evaluations of gene therapies are generally not being followed. Assessing the applicability and impact of the recommendations from this study may facilitate the implementation of consensus recommendations in future evaluations.
引用
收藏
页码:483 / 497
页数:15
相关论文
共 79 条
  • [1] Aballea Samuel, 2020, J Mark Access Health Policy, V8, P1822666, DOI 10.1080/20016689.2020.1822666
  • [2] Overcoming Challenges Facing Advanced Therapies in the EU Market
    Abou-El-Enein, Mohamed
    Elsanhoury, Ahmed
    Reinke, Petra
    [J]. CELL STEM CELL, 2016, 19 (03) : 293 - 297
  • [3] Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
    Almutairi, Abdulaali R.
    Alkhatib, Nimers A.
    Curiel-Lewandrowski, Clara
    Babiker, Hani M.
    Cranmer, Lee D.
    McBride, Ali
    Abraham, Ivo
    Mokoh
    [J]. JAMA DERMATOLOGY, 2019, 155 (01) : 22 - 28
  • [4] Review on mechanistic strategy of gene therapy in the treatment of disease
    Alnasser, Sulaiman M.
    [J]. GENE, 2021, 769
  • [5] Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
    Angelis, Aris
    Naci, Huseyin
    Hackshaw, Allan
    [J]. PHARMACOECONOMICS, 2020, 38 (12) : 1297 - 1308
  • [6] TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
    Annemans, Lieven
    Makady, Amr
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [7] Discounting in Economic Evaluations
    Attema, Arthur E.
    Brouwer, Werner B. F.
    Claxton, Karl
    [J]. PHARMACOECONOMICS, 2018, 36 (07) : 745 - 758
  • [8] The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective
    Bolous, Nancy S.
    Chen, Yichen
    Wang, Huiqi
    Davidoff, Andrew M.
    Devidas, Meenakshi
    Jacobs, Timothy W.
    Meagher, Michael M.
    Nathwani, Amit C.
    Neufeld, Ellis J.
    Piras, Bryan A.
    Rodriguez-Galindo, Carlos
    Reiss, Ulrike M.
    Bhakta, Nickhill
    [J]. BLOOD, 2021, 138 (18) : 1677 - 1690
  • [9] Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
    Broekhoff, Thomas F.
    Sweegers, Carly C. G.
    Krijkamp, Eline M.
    Mantel-Teeuwisse, Aukje K.
    Leufkens, Hubert G. M.
    Goettsch, Wim G.
    Vreman, Rick A.
    [J]. VALUE IN HEALTH, 2021, 24 (06) : 759 - 769
  • [10] The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018
    Bruce, Catherine Schuster
    Brhlikova, Petra
    Heath, Joseph
    McGettigan, Patricia
    [J]. PLOS MEDICINE, 2019, 16 (09)